Management of cutaneous vasculitis ranges from general measures to immunosuppressive and cytotoxic therapy

ISSN： 1172-0360

Source： Drugs & Therapy Perspectives, Vol.24, Iss.10, 2008-10, pp. : 9-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Characterization and Management of Cutaneous Side Effects Related to the Immunosuppressive Treatment in Solid Organ Recipients

Current Drug Targets, Vol. 18, Iss. 4, 2017-02 ,pp. : 436-446

Bentham Science Publishers

Access to resources Recommend Favorite

Rituximab: Cutaneous vasculitis: case report

Reactions Weekly, Vol. 1, Iss. 1255, 2009-01 ,pp. : 28-29

Adis International

Access to resources Recommend Favorite

Pharmacogenomic considerations for immunosuppressive therapy

By Yagil Yoram Yagil Chana

Pharmacogenomics, Vol. 4, Iss. 3, 2003-05 ,pp. : 309-319

Future Medicine

Access to resources Recommend Favorite

Immunosuppressive Therapy for Myelodysplastic Syndromes

Current Pharmaceutical Design, Vol. 18, Iss. 22, 2012-07 ,pp. : 3184-3189

Bentham Science Publishers

Access to resources Recommend Favorite

Cimicifuga: Cutaneous vasculitis: 2 case reports

Reactions Weekly, Vol. 1, Iss. 1151, 2007-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite